



BRINGING COGNITIVE CARE TO PRIMARY CARE

Introducing Cognivue®

A breakthrough in managing the global epidemic of late-life cognitive decline.

Cerebral Assessment Systems®- founded by Dr. Charles Duffy, Professor of Neurology at the University of Rochester-provides the world's first FDA cleared computerized dementia testing solution called *Cognivue*. To ensure a global impact, *Cognivue* is designed specifically for use in primary care-the lowest possible cost and most widely accessible patient care setting available. *Cognivue* is a quantum leap over decades-old question and answer testing, enabling a rapid and objective test to inexpensively measure and monitor brain health and detect the early signs of dementia.

Cognivue®
Cognitive Assessment Solution

Providers

No referrals. Now a rapid, office-based solution for routine brain health monitoring when indicated or patient requested.

- 10 tests in 10 minutes
- Self-administered
- Reimbursed

Patients and Family

Available to patients in any healthcare setting working with their personal physician who knows them best.

- Accessible testing across time and locations
- Immediate results
- One quantitative score of brain health

IDNs and Payors

Early dementia detection, promoting effective treatment and better outcomes.

- Treat reversible dementia
- Manage co-morbidities
- Avoid complications-polypharmacy and procedures

Industry

Rapid, standardized CRO brain health testing of new molecules.

- Global patient interface
- Cloud-based results storage and analytics
- Engaging PCPs in testing and monitoring of new treatments

Cognivue Advantages

Cognivue is based on 20 years of neurophysiology and psychophysical research that focuses on the early detection of late-life cognitive decline.

- First FDA-cleared dementia test
- Designed expressly for PCPs
- 10 tests in 10 minutes
- Easy to administer and simple to interpret
- Private and self-administered
- Reimbursable
- One-page, easy-to-interpret report
- One quantitative score of brain health
- Permanent local and cloud-based test storage for future comparisons
- All patient records are confidential

“ It is our goal to make the assessment of cognitive function as routine as having your blood pressure checked. ”

- Charles Duffy, MD, Ph. D., Founder and CEO of Cerebral Assessment Systems

Cognivue® Short-Form Specifications

Mobile Cart

Dimensions - 26" D x 22" W x 50" H

Weight - 50 lbs.

All-in-One Computer

Panel-20" WLED, 1600 x 900 HD

Networking-Ethernet LAN

10/100/1000, wireless 802.11n

Hard Drive: 500 GB

Mouse/Keyboard

Keyboard with integrated touchpad

Rotary Wheel (CogniWheel™)

USB 2.0

Voltage

100-240VAC, 50-60Hz

Safety Compliance

UL 60950-1, EN 60950 1:2001

EMC Compliance

FCC Class B Title 47, Parts 2 & 15,

Subpart B, CISPR 22:2003,

EN55024-1;2003

Frequently Asked Questions

How is *Cognivue* classified for use by the FDA?

"FDA classifies *Cognivue* as a Computerized Cognitive Assessment Aid: Prescription device that uses an individual's score(s) on a battery of cognitive tasks to provide an interpretation of the current level of "cognitive function."

Can I use *Cognivue* on all of my patients?

Cognivue testing is approved by the FDA for patients 55–95 years old.

Why is *Cognivue* a breakthrough brain health test?

Cognivue is the first-of-its-kind, objective, computer-based solution to rapidly assess, measure, and monitor brain function to detect early signs of dementia in the primary care setting.

What makes *Cognivue* practical for use in the doctor's office?

Cognivue was designed to be used specifically in primary care with four key attributes: 10 tests in 10 minutes, one-page report with one average score representing the performance on all sub-tests, patient administered, and physician reimbursement.

How does *Cognivue* testing compare to what is currently available?

Pivotal FDA studies demonstrated equal to or superior predictability and repeatability compared to standardized written and oral tests.

How does *Cognivue* differ from other cerebral assessment tools?

Cognivue is based on psychophysics directly linked to basic brain function. Responses can be related to physiological measures of brain function.

Are there common, treatable causes of dementia?

Common causes of treatable impairment include Obstructive Sleep Apnea (OSA), infection, endocrine disorders, organ failure, and mood disorders.

What is the reimbursement for *Cognivue* testing?

Code # 96120 is used for the cognitive assessment.